Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.  For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' financial performance and growth potential, including 2010 financial guidance and the sufficiency and use of Jazz Pharmaceuticals' cash resources, statements related to Jazz Pharmaceuticals' JZP-6 product candidate, including statements related to future regulatory matters and its potential commercialization, and statements related to the future development of new dosage forms of sodium oxybate.  These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. &
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DALLAS and NEW YORK ... (OTCBB: ACCP), a developer of new products for oncology ... mucositis, MuGard ® , has been featured in an ... Oral Mucositis Symptoms in Head and Neck Cancers."  Dr. ... mucositis, provides insight on the growing demand seen in ...
(Date:7/30/2014)... , July 30, 2014   Medical Equipment ... have been awarded a Department of Defense (US Army) ... to supply a mobile MRI diagnostic machine and technical ... Business (WOSB) through the Small Business Administration (SBA), Medical ... the field with the latest medical diagnostic equipment. The ...
(Date:7/30/2014)... SUNNYVALE, California , July 30, 2014 /PRNewswire/ ... GPU technology and CUDA programming expertise to big ... other markets  eInfochips, a leading engineering ... to clients to develop NVIDIA GPU-powered solutions for ... , high-performance computing (HPC), industrial ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... NATICK, Mass., May 6, 2011 Boston Scientific ... the launch and first implants of its ENERGEN™ ... implantable cardioverter defibrillators (ICDs) in Europe and other ... thinnest high-energy devices to treat heart failure and ...
... BD Diagnostics, a segment of BD (Becton, Dickinson and ... launch of the BD MAX™ Open System for molecular testing, ... developed assays and offer enhanced testing services that elevate the ... the launch announcement on the opening day of the 21st ...
Cached Medicine Technology:Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 2Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 3Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death 4BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 2BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 3BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians 4
(Date:7/31/2014)... The study, The Truth Behind Variation in ... care payments for four clinical areas—congestive heart failure, acute ... and knees). Using the definition of episodes of ... program, the study examines these clinical areas within the ... , “Our study reaffirms that, in most instances, the ...
(Date:7/30/2014)... Riverdale, NJ (PRWEB) July 31, 2014 ... in Macy’s ninth annual national “Shop For A Cause” ... For A Cause” is a unique one-day-only shopping event ... helped raise more than $44 million for charities across ... year’s event by purchasing shopping passes from Push to ...
(Date:7/30/2014)... Dayton, Ohio (PRWEB) July 31, 2014 ... welcome Douglas A. Fecher President and CEO, Wright-Patt Credit ... , Fecher, is a foremost financial CEO with an ... vice president of lending and later chief operating officer ... 2000, Fecher has led the Beavercreek-based Wright-Patt Credit Union ...
(Date:7/30/2014)... 31, 2014 WalkingSticksandCane.com has just ... The ladies will love the new European fashions and the ... These sticks and canes are from one from one of ... of the styles re unique and offer the consumer the ... Blackthorn Walking Sticks are some of the rarest and most ...
(Date:7/30/2014)... born with severe combined immunodeficiency (SCID) can be successfully ... to experts led by Memorial Sloan Kettering,s Richard J. ... transplant protocols. Their review will be published in the ... of Medicine . , SCID is a group of ... malfunction. When this breakdown occurs, babies no longer have ...
Breaking Medicine News(10 mins):Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3Health News:European Walking Sticks from WalkingSticksandCane.com 2Health News:Transplantation shown to be highly effective in treating immune deficiency in children 2
... Despite of the significant improvements in dialysis treatments, over ... U.S. Hemodialysis International, which published the// study, finds ... malnutrition. ,Large Body Mass Combats Effects ... what has been termed the “obesity paradox,” wherein obesity ...
... health crisis triggered by the death of over 40 ... institution's laboratory, has prompted Panamanian President// Martin Torrijos to ... ,Torrijos said that the government had since closed ... Body (CSS), permanently in a bid to win back ...
... a new study, septic shock—a dangerous, often deadly runaway ... research also suggests how a drug might// temper sepsis. ... been revealed in an experimental animal. ... Sabin Professor of Microbiology and Molecular Pathogenesis at NYU ...
... grow old in good health should have strong grip, not ... recent study.// ,A 40-year study of nearly 6000 ... nine factors that were good predictors of which middle-aged men ... ,The nine factors were: not being overweight, low blood sugar ...
... women who complain of severe itching and redness of skin ... intercourse that has been now confirmed by doctors as a ... present in semen. Thankfully doctors have given the hope to ... according to the report made in LiveScience. ,The ...
... More than 80,000 people in the United States are on ... for the death of a matching donor, but more and ... ,Last year nearly 7,000 people donated a kidney, segment of ... in need of a transplant. In fact at some major ...
Cached Medicine News:Health News:New Study Finds On/Off Switch for Septic Shock 2Health News:Keys to Good Health in Old Age Begins in Midlife 2Health News:See, men cause allergies in women after sex 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 2Health News:Researchers Study Reimbursing Living Organ Donors for Out-of-Pocket Expenses 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Permanent, sutureless, epicardial pacing leads...
Medicine Products: